Pfizer Inc. (NYSE:PFE) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Pfizer Inc. (NYSE:PFEGet Free Report) have been given a consensus rating of “Moderate Buy” by the sixteen ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation, five have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $32.00.

Several equities research analysts have recently weighed in on the company. Sanford C. Bernstein assumed coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Truist Financial decreased their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. Finally, UBS Group decreased their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th.

Get Our Latest Analysis on Pfizer

Insiders Place Their Bets

In other news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PFE. Retirement Wealth Solutions LLC purchased a new position in shares of Pfizer in the fourth quarter valued at $26,000. Gladius Capital Management LP increased its position in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP purchased a new position in shares of Pfizer in the second quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Pfizer in the third quarter valued at $35,000. Finally, Joseph Group Capital Management increased its position in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.86 on Tuesday. The company has a market capitalization of $152.19 billion, a P/E ratio of 36.29, a PEG ratio of 0.64 and a beta of 0.64. Pfizer has a twelve month low of $24.48 and a twelve month high of $31.54. The business has a 50 day simple moving average of $26.11 and a 200-day simple moving average of $27.94. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFEGet Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) earnings per share. As a group, equities analysts anticipate that Pfizer will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be given a $0.43 dividend. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.40%. Pfizer’s dividend payout ratio is presently 232.43%.

About Pfizer

(Get Free Report

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.